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Background. Major depressive disorder (MDD) is associated with signiﬁcant impairment in occupational functioning. This study
sought to determine which depressive symptoms and medication side eﬀects were perceived by patients with MDD to have the
greatest interference on work functioning. Methods. 164 consecutive patients with MDD by DSM-IV criteria completed a standard
assessment that included a self-rated questionnaire about the degree to which symptoms and side eﬀects interfered with work
functioning. Results. The symptoms perceived by patients as interfering most with work functioning were fatigue and low energy,
insomnia,concentrationandmemoryproblems,anxiety,andirritability.Themedicationsideeﬀectsratedasinterferingmostwith
work functioning were daytime sedation, insomnia, headache, and agitation/anxiety. There were no diﬀerences between men and
womeninsymptomsorsideeﬀectsthatwereperceivedasinterferingwithworkfunctioning.Limitations.Thiswasacross-sectional
study; only subjective assessments of work functioning were obtained; the fact that patients were using varied medications acts as a
potentialconfound.Conclusions.Speciﬁcdepressivesymptomsandmedicationsideeﬀectswereperceivedbypatientsasinterfering
more with occupational functioning than others. These factors should be considered in treatment selection (e.g., in the choice of
antidepressant) in working patients with MDD.
1.Introduction
Unipolar major depressive disorder (MDD) is among the
most common and disabling medical conditions. Many epi-
demiological studies have demonstrated the high prevalence
of MDD in the general population. For example, the Cana-
dian Community Health Survey (CCHS) recently reported a
one-year prevalence rate of 4.5% for MDD, indicating that
over 1.2 million Canadians suﬀer signiﬁcant distress and
impairment in functioning due to mood disorders [1].
Similar statistics are found for Europe [2] and the United
States [3]. Depression is currently the fourth leading medical
condition contributing to global burden of disease and is
estimated to rise to second by the year 2030 [4].
Given the high prevalence of MDD, increasing attention
is now being paid to the economic costs of depression.
The economic burden is, in part, attributable to individuals
with depression being unable to work, or absenteeism. For
example, one study reported that workers with MDD missed
an average of 32 days of work in a 12-month assessment
period [5], while another found that about 30% of work
disability claims in Canada were attributed to mental illness,
predominant depression, and other mood disorders [6].
However, the greater proportion of the total economic bur-
den of MDD lies in reduced productivity, or presenteeism, in
which the depressed individual remains in the work setting
but with productivity suﬀering both in quality and quantity
[7, 8]. In Canada, the economic costs of depression-related2 Depression Research and Treatment
presenteeism alone are estimated at over $5 billion annually
[9].
The CCHS also found that, in 2002, 79% of people ex-
periencing MDD in the previous year reported some inter-
ference with their work functioning [5]. It should not be
surprising that depression is associated with such signif-
icant occupational impairment. The constellation of core
symptoms of depression includes both physical (decreased
energy, sleep disturbance) and cognitive (reduced interest
and motivation, diﬃculty with concentration and attention)
symptoms that would be expected to impair functioning in
all types of work.
Several studies have explored which depressive symp-
toms predict occupational impairment. Some speciﬁc symp-
toms, such as low energy/fatigue, psychomotor disturbance,
and low interest/pleasure [10], and diﬃculty concentrat-
ing/ﬁdgety and feeling tired/sleep disturbance [11], have
b e e nf o u n dt op r e d i c ti m p a i r m e n ti nw o r kp r o d u c t i v i t y .
However, these studies examined nonclinical populations or
combined clinical and nonclinical subjects. As well, while
they statistically correlated self-rated symptom severity to
work impairment, these studies did not solicit the opinions
of subjects about which symptoms most aﬀected their work
performance, thus missing a potentially important aspect
of study. In fact, there is little available information about
theclinicallydepressedindividual’s subjectiveunderstanding
of symptomatic interference with occupational functioning.
Theobservedrelationshipbetweendepressivesymptomsand
work impairment can also be confounded by treatment,
which has not been examined in previous studies. Side
eﬀects (e.g., sedation, nausea, insomnia, etc.) associated with
antidepressant medications may also adversely aﬀect work
functioning, even if mood and other depressive symptoms
improve.
In this study, we sought to determine which depressive
symptoms and medication side eﬀects were subjectively
experienced by individuals with MDD as most impairing
their work functioning. Because of some studies showing
diﬀerences between men and women in the experience of
depressive symptoms [12], occupational stress [13, 14], and
occupationalimpairment[15–17],wealsoexaminedtherole
of gender.
2. Methods
2.1. Subjects. Consecutive patients attending a Mood Dis-
orders Clinic at a university teaching hospital completed
several questionnaires as part of their initial assessment.
Patients were referred from primary care physicians and
from community psychiatrists. Clinical assessments were
conducted by board-certiﬁed psychiatrists. Diagnoses were
assigned according to DSM-IV criteria based on clinical
interviews supplemented by a symptom check list and all
available medical information. Inclusion criteria for this
study included a DSM-IV diagnosis of major depressive dis-
order and a Quick Inventory of Depressive Symptomatology,
Self-rated (QIDS-SR) [18] score of 5 or higher, indicating
clinically signiﬁcant depressive symptoms. Patients with
bipolar disorder, or who did not do paid or volunteer work
(outside the home), were excluded. This study was approved
by the Clinical Research Ethics Board of the University of
British Columbia.
2.2. Assessment Measures. At their initial assessment, all
patients completed the QIDS-SR [18], a validated self-rated
scale to assess severity and type of depressive symptoms,
and the Sheehan Disability Scale [19]. In addition, patients
completed a questionnaire speciﬁcally developed for this
study that included two questions. The ﬁrst question was,
“IN THE PAST WEEK, how have the following symptoms
interfered with your ability to work? By work, we mean paid
work if you are employed, schoolwork if you are a student,
and housework if you are a homemaker.” Fifteen common
symptoms of depression (including all symptom criteria for
MDD) were listed, each rated on a 5-point Likert scale that
included the following responses: “Did not have symptom,”
“Not at all,” “Somewhat,” “Very much,” and ”So much that I
had to stop working.”
The second question was, “Sometimes people have side
eﬀects to medications. IN THE PAST WEEK, how have
the following side eﬀects interfered with you [sic]a b i l i t yt o
work? By work, we mean paid work if you are employed,
schoolwork if you are a student, and housework if you
are a homemaker.” Thirty six common side eﬀects (based
on a side eﬀect rating scale used in clinical trials) were
listed, each rated on a 5-point Likert scale that included the
following responses: “Did not have side eﬀect,” “Not at all,”
“Somewhat,” “Very much,” and “So much that I had to stop
working.”
The mean scores for these symptom and side eﬀect
items were examined by assigning values of 0, 1, 2, and 3,
respectively, to the latter four Likert responses. In addition,
foreachitem,wedeterminedwhethertherespondentratedit
as “clinically important” interference with work functioning,
deﬁned as a response of “Very much” or “So much that I had
to stop working.”
2.3. Statistical Analysis. A l lr e s u l t sa r er e p o r t e da sm e a n±
standard deviations (SD). Parametric comparisons were
conducted with t-tests, nonparametric comparisons with
Friedman’s tests, and chi-square tests with Fisher’s test as
appropriate. Because this was an exploratory study, no
corrections were utilized for multiple comparisons. All
analyses were conducted with SPSS v.16 [20].
3. Results
In a 4-month period, a total of 178 eligible subjects were
screenedattheclinic.Fourteenoftheeligiblepatientsdidnot
completeoneormoreofthequestionnaires,leavingatotalof
164 patients with complete data. Table 1 shows demographic
and assessment information for the sample. There were no
signiﬁcant diﬀerences between men and women in any of the
variables, including mean QIDS-SR and SDS scores. There
were also no diﬀerences in mean scores on the 3 individual
SDS items (data not shown).Depression Research and Treatment 3
Table 1: Demographic and assessment data on patients (N = 164) with major depressive disorder.
Variable (±SD) Men (N = 57) Women (N = 107) Total (N = 164)
Age (years) 41.1 ± 12.04 1 .7 ±13.04 1 .5 ±12.6
Marital status (%) (married/single/divorced/separated) 54/30/6/8 38/38/17/6 43/35/13/7
Number of episodes 3.0 ± 3.42 .4 ±5.42 .7 ±4.8
Duration of current episode (months) 6.8 ± 9.97 .7 ±7.17 .3 ±7.9
Number of psychotropic medications 1.9 ± 1.22 .0 ±1.12 .0 ±1.1
QIDS-SR mean score 14.5 ±5.41 5 .1 ±5.31 4 .9 ±5.3
SDS mean score 7.3 ± 2.47 .3 ±2.37 .3 ±2.3
Number of work days missed in past month 10.4 ± 12.01 0 .6 ±12.71 0 .5 ±12.3
SD: standard deviation; QIDS-SR: quick inventory of depressive symptomatology, self-rated; SDS: Sheehan disability scale.
Table 2 shows the summary of responses from the
questionnaire about depressive symptoms and their eﬀect on
work functioning. Most of the symptoms were commonly
experienced by patients, with the prevalence rate ranging
from 98% of the sample endorsing low mood to 66%
endorsing suicidal ideation. All symptoms were associated
with some subjective interference with work functioning.
However, the proportion of patients reporting clinically
important interference in work functioning with individual
symptoms varied, ranging from 59% (lack of motivation)
to 19% (suicidal ideation). Clinically important impairment
in work functioning was endorsed by more than half of
the sample as associated with lack of motivation, low
energy, low mood, feeling physically slowed down, and
anxious/tense/nervous.
Table 3 shows the summary of responses from the
question about medication side eﬀects and interference with
work functioning, in those side eﬀects that were experienced
by at least 10% of the sample. The most troubling side
eﬀects associated with clinically important interference with
work functioning were daytime sleepiness, trouble sleeping,
headache, and anxiety/agitation.
A series of analyses compared responses between men
and women. For individual depressive symptoms, there
were no signiﬁcant diﬀerences between men and women
in the mean scores of interference with work functioning.
In the rates of clinically important interference with work
functioning (either “Very much” or “So much that I had to
stop working” responses for each item), only “Trouble with
memory” was signiﬁcantly diﬀerent, with women reporting
greater interference with functioning than men (45% versus
27%, resp., χ2 = 4.6, df = 1, P<0.04). A nonsigniﬁcant
trend was observed for women to endorse “Feeling physically
sloweddown”asmoreinterferingwithfunctioningthanmen
(57% versus 43%, resp., χ2 = 2.9, df = 1, P<0.09). There
were no signiﬁcant diﬀerences between women and men for
any medication side eﬀects, in either the mean scores of
interference with work functioning or in rates of clinically
important interference.
4. Discussion
This study shows that symptoms of depression are com-
monly perceived by patients as signiﬁcantly interfering with
their occupational functioning, but that diﬀerent symptoms
do so to diﬀerent degrees. Inspection of our data at an item
level identiﬁes three major symptom clusters that interfere
most with functioning at work: anergia (lack of motivation;
low energy; feeling physically slowed down; sleepy during
the day), tension (anxious/tense/nervous; irritability/anger),
and cognitive diﬃculty (trouble concentrating; trouble
with memory). Clinically signiﬁcant work impairment was
endorsed in at least one of the individual symptoms within
these symptom clusters by 66%, 54%, and 52%, respectively,
ofpatients inthis study. Some depressive symptoms wereless
likely to interfere with work functioning. For example, the
symptom of “suicidal thoughts” was experienced by 66% of
patients, but was rated by only 19% as clinically interfering
with occupational functioning.
These results are generally consistent with those from
other studies that have examined the eﬀect of individual
depressive symptoms on work productivity. In contrast to
our study, in which patients self-reported the degree of
work impairment from individual symptoms, other studies
correlated scores from patient-rated scales of symptom
severitywithscalesassessingworkproductivity.Forexample,
Sanderson and colleagues [10] studied a nonclinical sample
of 431 employees at 10 Australian call centres and examined
depressive symptoms endorsed on a rating scale (the Patient
Health Questionnaire, PHQ-9) and eﬀects on work produc-
tivity, as measured by the work limitations questionnaire
(WLQ)[11, 21]. Three symptoms (tired or little energy, little
interest or pleasure, and psychomotor disturbance) were
found to be signiﬁcant predictors for presenteeism, while
symptoms of low mood, sleep disturbance, and appetite
disturbance were not predictive of work impairment. Our
results (in patients with MDD) are very similar to theirs (in
a nonclinical sample), with the exception that low mood
and sleep disturbance were both identiﬁed by patients as
interfering with work functioning in the current study.
Similarly, in a sample of patients screened at a primary
careclinic,Lernerandcolleagues[11]examinedtherelation-
ship of some composite symptoms of depression (measured
by ratings from the PHQ-9) to productivity loss (measured
by the WLQ). The sample of 389 employed people included
246 who were depressed: 64 with dysthymia, 89 with MDD,
and 93 with double depression. That study examined two
speciﬁc symptom clusters: concentration/ﬁdget (comprised
of 2 items on the PHQ-9: diﬃculty concentrating and
psychomotor change (ﬁdgety or moving too slowly)) and4 Depression Research and Treatment
Table 2: Summary of responses (N = 164) from questionnaire relating symptoms to interference with work functioning.
Symptom % of sample experiencing symptom Mean score SD Clinically important interference1 (%)
Lack of motivation 93 1.78 0.91 59
Low energy 96 1.72 0.87 58
Low mood 98 1.68 0.88 55
Feeling physically slowed down 94 1.50 0.92 52
Anxious/tense/nervous 96 1.55 0.90 50
Trouble concentrating 96 1.48 0.80 45
Sleepy during the day 88 1.31 0.85 40
Trouble with memory 93 1.31 0.77 39
Trouble sleeping at night 84 1.30 0.93 39
Feeling guilty/ashamed 88 1.24 0.97 38
Irritability/anger 91 1.26 0.91 36
Physical pain 76 1.18 1.10 35
Sleeping too much 80 1.26 1.00 31
Poor appetite 69 0.95 0.97 28
Suicidal thoughts 66 0.79 0.92 19
1Deﬁnedasaresponseof“Verymuch”or“SomuchthatIhadtostopworking”tothefollowingquestion:“Inthepastweek,howhavethefollowingsymptoms
interfered with your ability to work?”
SD: standard deviation.
Table 3: Summary of responses (N = 164) from questionnaire relating medication side eﬀects (>9% prevalence) to interference in work
functioning.
Medication side eﬀect % of sample experiencing side eﬀect Mean SD Clinically important interference1 (%)
Daytime sleepiness 19 1.87 0.88 74
Trouble sleeping 26 1.84 0.92 73
Headache 22 1.67 0.98 59
Anxiety/agitation 14 1.74 1.10 57
Nausea/stomach upset 17 1.18 1.02 29
Weight loss/gain 18 0.87 0.97 17
Diarrhea/constipation 20 0.82 0.85 15
Sexual problems 32 0.08 0.30 0
1Deﬁnedasaresponseof“Verymuch”or“SomuchthatIhadtostopworking”tothefollowingquestion:“Inthepastweek,howhavethefollowingsymptoms
interfered with your ability to work?”
SD, standard deviation.
tired/sleep problems (comprised of 2 items on the PHQ-9:
feeling tired and having diﬃculty sleeping). Both symptom
clusters were associated with signiﬁcant loss of productivity,
and the cluster of tired/sleep problems was also associated
with days missed from work.
Antidepressant medications are widely used to treat
working people with MDD. For example, in a sample of
employees on depression-related short-term disability, 58%
were prescribed antidepressants [22]. Our study found that
many medication side eﬀects are endorsed by patients as
interfering with work functioning. The most troublesome
side eﬀects were daytime sedation, insomnia, headache, and
anxiety/agitation. We note that these side eﬀects should be
considered as nonspeciﬁc, since the patients were taking
diﬀerent antidepressants and some were on multiple medi-
cations. Some medication side eﬀects were commonly expe-
rienced by patients but were not associated with impairment
in work functioning, for example, sexual side eﬀects were
endorsed by 32% of the sample, but 0% found these to be
associated with clinically signiﬁcant interference at work.
Some studies have found diﬀerences between men and
women in depressive symptomatology and eﬀects on work
functioning, while others have not. For example, women
have been found to have more work absence days than
men [15]. Our results showed little eﬀect of gender on
self-perceived work interference, whether from depressive
symptoms or from medication side eﬀects. Only “trouble
with memory” was reported by more women than men as
interfering with work functioning, and this may have been
a type I error since there was no statistical correction for
multiple comparisons.
This study has a number of limitations, including the use
of a cross-sectional design, the self-report nature of the data
without objective assessment of occupational performance,
the varied nature of work experienced by respondents,
and the use of multiple and varied medication regimens
by the patients. We also did not have information on
whether patients were engaged in psychosocial treatments
(e.g., cognitive behavioural therapy) that may aﬀect work
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to our ﬁndings. First, since numerous depressive symp-
toms are perceived by patients to be associated with work
impairment, occupational functioning should be routinely
assessed(viastandardized,validatedassessmentscales)inthe
management of people who are clinically depressed. Second,
treatment for MDD in working patients should address
the symptoms that interfere most with work functioning,
including anergia, tension, and concentration diﬃculty.
Monitoring of symptoms and functioning during treatment
is also important, to ensure that work functioning returns to
premorbid status and is not aﬀectedby residual symptoms of
depression.Finally,sincethesideeﬀectproﬁlesforindividual
antidepressantsarequitediﬀerent[23],thechoiceofmedica-
tion for working patients should take into account those side
eﬀects that most impair work functioning. Antidepressants
thatminimize theseside eﬀects(daytimesedation,insomnia,
headache, and anxiety/agitation) should be the preferred
options for working patients with MDD.
In summary, patients with MDD report that the depres-
sive symptom clusters of anergia, tension, and concentration
diﬃcultyaremostinterferingwithoccupationalfunctioning,
with no diﬀerences found between men and women. In
the clinical management of working patients with MDD,
it will be important to ensure that these symptoms are
addressed by treatment. In addition, if pharmacotherapy
is used, medications should be chosen to avoid those side
eﬀects(sedation, insomnia, headache, and anxiety/agitation)
that are reported by patients as most interfering with work
functioning.
Funding
No external funds were sought or received for this study or
paper.
Conﬂict of Interests
Dr. R. W. Lam is on Speaker/Advisory Boards for, or
has received research funds from, AstraZeneca, Biovail,
Canadian Institutes of Health Research, Canadian Network
for Mood and Anxiety Treatments, Canadian Psychiatric
Association Foundation, Eli Lilly, Litebook Company Ltd.,
Lundbeck, Lundbeck Institute, Michael Smith Foundation
for Health Research, Pﬁzer, Servier, St. Jude Medical, Takeda,
and UBC Institute of Mental Health/Coast Capital Savings.
Dr. D. J. Bond has received research grants from the
Canadian Institutes of Health Research and the UBC Insti-
tute of Mental Health/Coast Capital Savings and has received
honoraria from AstraZeneca and the Canadian Network for
Mood and Anxiety Treatments.
Dr. L. N. Yatham is on Speaker/Advisory Boards for,
or has received research grants from, AstraZeneca, Bristol
Myers Squibb, Canadian Institutes of Health Research,
Canadian Network for Mood and Anxiety Treatments, Eli
Lilly, GlaxoSmithKline, Janssen, Michael Smith Foundation
for Health Research, Novartis, Pﬁzer, Ranbaxy, Scherring
Plough, Servier, and Stanley Foundation. All other authors
declare they have no conﬂict of interests.
Acknowledgments
The authors would like to acknowledge their appreciation
to the patients attending the UBC Hospital Mood Disorders
Centre for their participation in this study. E. E. Michalak is
supported by a New Investigator Award from the Canadian
Institutes for Health Research.
References
[1] S. B. Patten, L. W. Jian, J. V. A. Williams et al., “Descriptive
epidemiology of major depression in Canada,” Canadian
Journal of Psychiatry, vol. 51, no. 2, pp. 84–90, 2006.
[2] J. Alonso, M. C. Angermeyer, S. Bernert et al., “12-Month
comorbidity patterns and associated factors in Europe: results
from the European Study of the Epidemiology of Mental
Disorders (ESEMeD) project,” Acta Psychiatrica Scandinavica.
Supplementum, vol. 420, pp. 28–37, 2004.
[3] R. C. Kessler, P. Berglund, O. Demler et al., “The epidemiology
of major depressive disorder: results from the National
Comorbidity Survey Replication (NCS-R),” JAMA, vol. 289,
no. 23, pp. 3095–3105, 2003.
[4] C. D. Mathers and D. Loncar, “Projections of global mortality
and burden of disease from 2002 to 2030,” PLoS Medicine, vol.
3, no. 11, article e442, 2006.
[5] H. Gilmour and S. B. Patten, “Depression and work impair-
ment,” Health Reports, vol. 18, no. 1, pp. 9–22, 2007.
[6] C. S. Dewa, A. Lesage, P. Goering, and M. Craveen, “Nature
and prevalence of mental illness in the workplace,” Health-
carePapers, vol. 5, no. 2, pp. 12–25, 2004.
[7] G. Aronsson and K. Gustafsson, “Sickness presenteeism:
prevalence, attendance-pressure factors, and an outline of a
model for research,” Journal of Occupational and Environmen-
tal Medicine, vol. 47, no. 9, pp. 958–966, 2005.
[8] J.J.Collins,C.M.Baase,C.E.Shardaetal.,“Theassessmentof
chronic health conditions on work performance, absence, and
total economic impact for employers,” Journal of Occupational
and Environmental Medicine, vol. 47, no. 6, pp. 547–557, 2005.
[9] T. Stephens and N. Joubert, “The economic burden of mental
health problems in Canada,” Chronic Diseases in Canada, vol.
22, no. 1, pp. 18–23, 2001.
[10] K. Sanderson, E. Tilse, J. Nicholson, B. Oldenburg, and N.
Graves, “Which presenteeism measures are more sensitive to
depression and anxiety?” Journal of Aﬀective Disorders, vol.
101, no. 1–3, pp. 65–74, 2007.
[11] D. Lerner, D. A. Adler, H. Chang et al., “The clinical and
occupational correlates of work productivity loss among
employed patients with depression,” Journal of Occupational
and Environmental Medicine, vol. 46, no. 6, pp. S46–S55, 2004.
[12] S. E. Romans, J. Tyas, M. M. Cohen, and T. Silverstone,
“Gender diﬀerences in the symptoms of major depressive
disorder,” Journal of Nervous and Mental Disease, vol. 195, no.
11, pp. 905–911, 2007.
[13] C. Liu, P. E. Spector, and L. Shi, “Use of both qualitative
and quantitative approaches to study job stress in diﬀerent
gender and occupational groups,” Journal of Occupational
Health Psychology, vol. 13, no. 4, pp. 357–370, 2008.
[14] E. Sj¨ ogren, M. Kristenson, K. Ekberg et al., “Can gender diﬀer-
ences in psychosocial factors be explained by socioeconomic
status?” Scandinavian Journal of Public Health,v o l .3 4 ,n o .1 ,
pp. 59–68, 2006.
[15] C. S. Dewa, E. Lin, M. Kooehoorn, and E. Goldner, “Asso-
ciation of chronic work stress, psychiatric disorders, and6 Depression Research and Treatment
chronic physical conditions with disability among workers,”
Psychiatric Services, vol. 58, no. 5, pp. 652–658, 2007.
[ 1 6 ]J .W i e c l a w ,E .A g e r b o ,P .B .M o r t e n s e n ,a n dJ .P .B o n d e ,
“Occupational risk of aﬀective and stress-related disorders
in the Danish workforce,” Scandinavian Journal of Work,
Environment and Health, vol. 31, no. 5, pp. 343–351, 2005.
[ 1 7 ]J .W i e c l a w ,E .A g e r b o ,P .B oM o r t e n s e n ,H .B u r r ,F .T u c h s e n ,
and J. P. Bonde, “Psychosocial working conditions and the risk
of depression and anxiety disorders in the Danish workforce,”
BMC Public Health, vol. 8, article 280, 2008.
[18] A. J. Rush, M. H. Trivedi, H. M. Ibrahim et al., “The
16-item Quick Inventory of Depressive Symptomatology
(QIDS), clinician rating (QIDS-C), and self-report (QIDS-
SR): a psychometric evaluation in patients with chronic major
depression,” Biological Psychiatry, vol. 54, no. 5, pp. 573–583,
2003.
[19] A.C.Leon,M.Olfson,L.Portera,L.Farber,andD.V.Sheehan,
“Assessing psychiatric impairment in primary care with the
Sheehan Disability Scale,” International Journal of Psychiatry
in Medicine, vol. 27, no. 2, pp. 93–105, 1997.
[20] SPSS, SPSS for Windows, v.11.0, SPSS, Chicago, Ill, USA, 2004.
[ 2 1 ]D .L e r n e r ,B .C .A m i c k ,W .H .R o g e r s ,S .M a l s p e i s ,K .B u n g a y ,
and D. Cynn, “The work limitations questionnaire,” Medical
Care, vol. 39, no. 1, pp. 72–82, 2001.
[22] C. S. Dewa, J. S. Hoch, P. Goering, E. Lin, and M. Paterson,
“Use of antidepressants among Canadian workers receiving
depression-related short-term disability beneﬁts,” Psychiatric
Services, vol. 54, no. 5, pp. 724–729, 2003.
[23] R. W. Lam, S. H. Kennedy, S. Grigoriadis et al., “Canadian
Network for Mood and Anxiety Treatments (CANMAT)
Clinical guidelines for the management of major depressive
disorder in adults. III. Pharmacotherapy,” Journal of Aﬀective
Disorders, vol. 117, supplement 1, pp. S26–S43, 2009.